Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Gilead Sciences, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Gilead Sciences, Inc. (GILD) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. (“Gilead” or “the Company”) (NASDAQ: GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Gilead has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On June 10, 2025, Gilead issued a press release announcing that “[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead’s HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]” specifying that “[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.” On this news, Gilead’s stock price fell $2.91 per share, or 2.58%, to close at $110.09 per share on June 10, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Gilead securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
How Did Gilead Sciences, Inc. (GILD) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”